July 6, 2018

Please reload

Recent Posts

FDA Comments on Recently Released Rare Disease Guidance for Industry

September 16, 2015

Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently...

1/2
Please reload

Featured Posts

Orphan drug market to double as Pharma rethinks business model

August 7, 2017

The global orphan drug market is expected to double between 2016 and 2022 to $209bn as Pharma rethinks its business model away from blockbusters towards niche patient populations and orphan diseases, according to a new report.

 

A combination of drivers, including market saturation, pricing pressures and stricter reimbursement criteria, in addition to generic/biosimilar competition has forced Pharma to shift focus, according to the Epi Analyzer report by intelligence provider Evaluate.

 

To read the full article, please click on the following link: https://www.drugtargetreview.com/news/24360/orphan-drug-market-double/

Please reload

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info: info@patagoniarx.com

© 2019 by Patagonia Pharmaceuticals, LLC